NV-387
MPox / Smallpox
Key Facts
About NanoViricides
NanoViricides is pioneering a 'post-immunotherapeutic' platform to combat viral diseases with its unique nanoviricide technology, which mimics host cell receptors to trap and dismantle viruses. The company has advanced its lead broad-spectrum candidate, NV-387, into a Phase 2 trial for MPox in the Democratic Republic of Congo and maintains a deep pipeline targeting herpesviruses, HIV, influenza, and neglected tropical diseases. With its own cGMP-capable manufacturing facility in Shelton, CT, NanoViricides aims to control both extracellular virus spread and intracellular replication, addressing a multi-billion dollar market for antiviral therapeutics.
View full company profileAbout NanoViricides
NanoViricides is pioneering a 'post-immunotherapeutic' platform to combat viral diseases with its unique nanoviricide technology, which mimics host cell receptors to trap and dismantle viruses. The company has advanced its lead broad-spectrum candidate, NV-387, into a Phase 2 trial for MPox in the Democratic Republic of Congo and maintains a deep pipeline targeting herpesviruses, HIV, influenza, and neglected tropical diseases. With its own cGMP-capable manufacturing facility in Shelton, CT, NanoViricides aims to control both extracellular virus spread and intracellular replication, addressing a multi-billion dollar market for antiviral therapeutics.
View full company profileAbout NanoViricides
NanoViricides is pioneering a 'post-immunotherapeutic' platform to combat viral diseases with its unique nanoviricide technology, which mimics host cell receptors to trap and dismantle viruses. The company has advanced its lead broad-spectrum candidate, NV-387, into a Phase 2 trial for MPox in the Democratic Republic of Congo and maintains a deep pipeline targeting herpesviruses, HIV, influenza, and neglected tropical diseases. With its own cGMP-capable manufacturing facility in Shelton, CT, NanoViricides aims to control both extracellular virus spread and intracellular replication, addressing a multi-billion dollar market for antiviral therapeutics.
View full company profileAbout NanoViricides
NanoViricides is pioneering a 'post-immunotherapeutic' platform to combat viral diseases with its unique nanoviricide technology, which mimics host cell receptors to trap and dismantle viruses. The company has advanced its lead broad-spectrum candidate, NV-387, into a Phase 2 trial for MPox in the Democratic Republic of Congo and maintains a deep pipeline targeting herpesviruses, HIV, influenza, and neglected tropical diseases. With its own cGMP-capable manufacturing facility in Shelton, CT, NanoViricides aims to control both extracellular virus spread and intracellular replication, addressing a multi-billion dollar market for antiviral therapeutics.
View full company profile